Janssen Cilag Ltd, in agreement with the other UK marketing authorisation holders of topiramate (including Zydus UK) and the Medicines and Healthcare products Regulatory Agency (MHRA), are contacting you to inform you of the implementation of a Pregnancy Prevention Programme (PPP) for the use of topiramate-containing medicinal products in patients of childbearing potential. This PPP is being implemented following a review of safety data relating to the use of topiramate in pregnancy.